Clinical Reasoning: Assessing New Neurologic Deficits in Patients With Hematologic Malignancy on Bruton Tyrosine Kinase Inhibitor Therapy.

Nelson TA, Murthy NK, Martinez-Lage Alvarez M, Abramson J, Branagan AR, Ji Y, Chen YA, Letourneau AR, Nahed BV, Arrillaga-Romany IC, Wang N, Dietrich J.